- Home
- EW
as 08-01-2025 4:00pm EST
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
| Founded: | 1958 | Country: | United States |
| Employees: | N/A | City: | IRVINE |
| Market Cap: | 44.8B | IPO Year: | 2000 |
| Target Price: | $85.00 | AVG Volume (30 days): | 5.1M |
| Analyst Decision: | Buy | Number of Analysts: | 20 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 7.02 | EPS Growth: | 188.87 |
| 52 Week Low/High: | $59.41 - $83.00 | Next Earning Date: | 07-24-2025 |
| Revenue: | $5,685,100,000 | Revenue Growth: | 9.49% |
| Revenue Growth (this year): | 12.97% | Revenue Growth (next year): | 9.65% |
Stock Insider Trading Activity of Edwards Lifesciences Corporation (EW)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Chopra Daveen | EW | CVP, TMTT | May 22 '25 | Sell | $75.08 | 1,500 | $112,612.50 | 33,496 | |
| Ullem Scott B. | EW | CVP, Chief Financial Officer | May 7 '25 | Sell | $74.40 | 11,250 | $837,034.88 | 41,098 |
Latest Edwards Lifesciences Corporation News
EW Breaking Stock News: Dive into EW Ticker-Specific Updates for Smart Investing
Insider Monkey
3 days ago
Baron Health Care Fund Reacquired Edwards Lifesciences Corporation (EW) in Q2. Here’s Why
MT Newswires
4 days ago
Edwards Lifesciences Shares Rise After BTIG Upgrade
MT Newswires
5 days ago
BTIG Upgrades Edwards Lifesciences to Buy From Neutral, Price Target is $100
MT Newswires
5 days ago
CICC Adjusts Price Target on Edwards Lifesciences to $100 From $80, Maintains Outperform Rating
MT Newswires
5 days ago
Daiwa Securities Upgrades Edwards Lifesciences to Outperform From Neutral, Adjusts PT to $89 From $77
MT Newswires
5 days ago
Edwards Lifesciences Insider Sold Shares Worth $326,901, According to a Recent SEC Filing
Zacks
5 days ago
ENSG's Q2 Earnings Beat on Higher Occupancy Rates, Stock Up 9%
MT Newswires
6 days ago
Rothschild & Co Redburn Adjusts Price Target on Edwards Lifesciences to $85 From $81, Maintains Buy Rating
Compare EW vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EW Edwards Lifesciences Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.